Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
The Conspicuity of Crispr-Cpf1 System As a Significant Breakthrough in Genome Editing Publisher Pubmed



Bayat H1, 2 ; Modarressi MH3 ; Rahimpour A1, 2
Authors

Source: Current Microbiology Published:2018


Abstract

Clustered regularly interspaced short palindromic repeats (CRISPR)—CRISPR-associated protein (Cas) is a microbial adaptive immune system. CRISPR-Cas systems are classified into two main classes and six types. Cpf1 is a putative type V (class II) CRISPR effector, which has revolutionized the genome editing approaches through multiple distinct features such as using T-rich protospacer-adjacent motif, applying a short guide RNA lacking trans-activating crRNA, introducing a staggered double-strand break, and possessing RNA processing activity in addition to DNA nuclease activity. In the present review, we attempt to highlight most recent advances in CRISPR-Cpf1 (CRISPR-Cas12a) system in particular, considering ground expeditions of the nature and the biology of this system, introducing novel Cpf1 variants that have broadened the versatility and feasibility of CRISPR-Cpf1 system, and lastly the great impact of the CRISPR-Cpf1 system on the manipulation of the genome of prokaryotic, mammalian, and plant models is summarized. With regard to recent developments in utilizing the CRISPR-Cpf1 system in genome editing of various organisms, it can be concluded with confidence that this system is a reliable molecular toolbox of genome editing approaches. © 2017, Springer Science+Business Media, LLC, part of Springer Nature.
Other Related Docs
6. Crispr Pioneers Win 2020 Nobel Prize for Chemistry, Iranian Journal of Public Health (2020)
10. The Impact of Crispr-Cas System on Antiviral Therapy, Advanced Pharmaceutical Bulletin (2018)
15. Nanoparticles-Mediated Crispr/Cas9 Delivery: Recent Advances in Cancer Treatment, Journal of Drug Delivery Science and Technology (2020)
17. Crispr-Interceded Cho Cell Line Development Approaches, Biotechnology and Bioengineering (2023)